ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 403
- 试验地点
- 5
- 主要终点
- Number of Participants With Treatment Responses Based on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report Scale (QIDS-SR-16)
研究概览
简要总结
The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as primary and secondary outcome measures.
详细描述
Patients with treatment resistant depression who meet all inclusion criteria and do not meet any exclusion criteria will be randomized to either electroconvulsive therapy (ECT) three times per week or ketamine infusion two times per week. Patients will answer questionnaires about their symptoms prior to treatments. The acute treatment phase of the study will last three to five weeks. Depending on response to treatment, some patients will be followed for an additional six months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Due to the nature of the study treatments it is not possible to blind patients or investigators.
入排标准
- 年龄范围
- 21 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent before any study related procedures are performed
- •Inpatients or outpatients referred by their providers for ECT treatment and eligible for ECT treatment
- •Males/females at least 21 years of age but no older than 75 years of age
- •Meet DSM-5 criteria for Major Depressive Episode as determined by both:
- •A. a clinician's diagnostic evaluation and B. confirmed with the MINI International Neuropsychiatric Interview (MINI 7.0.2)
- •A current depressive episode that has lasted a minimum of 4 weeks
- •Meet all of the following criteria on symptom rating scales at screening:
- •A. Montgomery Asberg Depression Rating Scale (MADRS) score >20 B. Young Mania Rating Scale (YMRS) of ≤ 5 C. Montreal Cognitive Assessment (MoCA) of ≥18
- •Have had ≥2 adequate trials of antidepressants or augmentation strategies during their lifetime. An adequate trial is defined as 4 weeks of medication at the minimum FDA approved dose. This will be equal to a trial rating of 3 or more.
- •In the opinion of the investigator, the patient is willing and able to comply with scheduled visits, treatment plan, and other trial procedures for the duration of the study
排除标准
- •Meet DSM-5 criteria for bipolar disorder, schizophrenia, schizophreniform disorder, schizoaffective disorder, mental retardation, or pervasive developmental disorder
- •Meets any exclusion criteria for ECT or ketamine treatment as described in the clinical guidelines or according to investigator judgment
- •The patient is pregnant or breast feeding
- •The patient has a severe medical illness or severe neurological disorder
- •The patient has a known ketamine allergy or is taking a medication that may interact with ketamine
- •Diagnosis of major depressive disorder with psychotic features during the current depressive episode
- •Unable to give informed consent
- •Was previously enrolled/randomized into the trial
研究组 & 干预措施
electroconvulsive therapy (ECT)
Treatments will be given 3 times a week up to a total of 9 treatments over 3 - 5 weeks. Initial ECT treatment is Right Unilateral (RUL) ultra-brief pulse at 6X seizure threshold. Seizure threshold and dose can be increased per investigator and patient discretion.
干预措施: electroconvulsive therapy (ECT) (Procedure)
ketamine infusion
Treatments will be given 2 times a week up to a total of 6 treatment over 3 - 5 weeks. Initial standard dose will be 0.5 mg/kg infusion over 40 min. The dose can be modified if clinically warranted per investigator and patient discretion.
干预措施: Ketamine (Drug)
结局指标
主要结局
Number of Participants With Treatment Responses Based on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report Scale (QIDS-SR-16)
时间窗: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 3-5 weeks
Response is defined as at least a 50% improvement in the QIDS-SR-16 scale from baseline to the End of Treatment visit. The End of Treatment visit will occur 3-5 weeks after the Baseline visit.
次要结局
- Number of Participants With Treatment Responses Based on the Montgomery-Åsberg Rating Scale (MADRS)(Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 3-5 weeks)
研究者
Bo Hu
Investigator
The Cleveland Clinic